These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 22771768)

  • 1. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
    Zhang W; Zhang W; Li Z; Hao J; Zhang Z; Liu L; Mao N; Miao J; Zhang L
    Pharmacol Biochem Behav; 2012 Jan; 100(3):361-9. PubMed ID: 21993310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model.
    Dobarro M; Orejana L; Aguirre N; Ramírez MJ
    Neuropharmacology; 2013 Jan; 64():137-44. PubMed ID: 22824191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR
    Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice.
    Sierksma AS; Prickaerts J; Chouliaras L; Rostamian S; Delbroek L; Rutten BP; Steinbusch HW; van den Hove DL
    Neurobiol Aging; 2013 Jan; 34(1):319-37. PubMed ID: 22738723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
    Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
    Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
    Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E
    Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
    García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
    Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice.
    Zhang J; Guo J; Zhao X; Chen Z; Wang G; Liu A; Wang Q; Zhou W; Xu Y; Wang C
    Behav Brain Res; 2013 Aug; 250():230-7. PubMed ID: 23685322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice.
    Bollen E; Vanmierlo T; Akkerman S; Wouters C; Steinbusch HM; Prickaerts J
    Behav Brain Res; 2013 Nov; 257():8-12. PubMed ID: 24070857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
    Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
    Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
    Gong B; Vitolo OV; Trinchese F; Liu S; Shelanski M; Arancio O
    J Clin Invest; 2004 Dec; 114(11):1624-34. PubMed ID: 15578094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease.
    Wei C; Zhang W; Zhou Q; Zhao C; Du Y; Yan Q; Li Z; Miao J
    Neurochem Res; 2016 Aug; 41(8):1924-38. PubMed ID: 27072684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP/cGMP pathway.
    Chen L; Liu K; Wang Y; Liu N; Yao M; Hu J; Wang G; Sun Y; Pan J
    Eur J Pharmacol; 2021 Jan; 891():173768. PubMed ID: 33271150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction.
    Zhang W; Bai M; Xi Y; Hao J; Liu L; Mao N; Su C; Miao J; Li Z
    Free Radic Biol Med; 2012 Apr; 52(8):1443-52. PubMed ID: 22342520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels.
    Timmer NM; van Dijk L; van der Zee CE; Kiliaan A; de Waal RM; Verbeek MM
    Neurobiol Dis; 2010 Oct; 40(1):340-7. PubMed ID: 20600909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.